Abstract:Human epidemiological studies have provided compelling evidence that the risk of developing schizophrenia is significantly enhanced following prenatal and/or perinatal exposure to various environmental insults, including maternal exposure to stress, infection and/or immune activation, nutritional deficiencies and obstetric complications. Based on these associations, a great deal of interest has been centered upon the establishment of neurodevelopmental animal models which are based on prenatal and/or perinatal exposure to such environmental stimuli. In the present review, we describe this relatively novel class of epidemiology-based animal models in relation to the etiology, neurobiology and psychopharmacology of schizophrenia. Thereby, we discuss the general design and practical implementation of these models, and we provide an integrative summary of experimental findings derived from diverse epidemiology-based models, including models of maternal exposure to psychological stress, glucocorticoid treatment, viral infection, immune activating agents, protein deprivation, vitamin D deficiency, as well as models of obstetric complications in the form of birth by Caesarian section and perinatal/postnatal hypoxia. We highlight that the long-term consequences of prenatal exposure to these environmental challenges in animals successfully capture a broad spectrum of structural and functional brain abnormalities implicated in schizophrenia, some of which can be normalized by acute and/or chronic antipsychotic drug treatment. We thus conclude that epidemiology-driven neurodevelopmental models of schizophrenia are characterized by a high level of face, construct and predictive validity, including intrinsic etiological significance to the disorder. They also fulfill the expectation of the neurodevelopmental theory, such that the effects of prenatal environmental insults often only emerge after puberty. Epidemiologically based animal models not only provide indispensable experimental tools to test the hypothesis of causality in human epidemiological associations, but they also offer important new avenues for the elucidation of neurobiological, neuroendocrine and neuroimmunological mechanisms involved in the etiopathogenesis of schizophrenia and related disorders.

Animal Models of Maternal Immune Activation in Depression Research

A comprehensive approach to modeling maternal immune activation in rodents

Maternal immune activation in rodent models: A systematic review of neurodevelopmental changes in gene expression and epigenetic modulation in the offspring brain

Animal models of major depression and their clinical implications

Animal Models of Depression: What Can They Teach Us about the Human Disease?

Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models

Animal models for depression and the mismatch hypothesis of disease

Animal Models of Depression: Molecular Perspectives

Global metabolic profiles in a non-human primate model of maternal immune activation: implications for neurodevelopmental disorders

Using animal models to disentangle the role of genetic, epigenetic, and environmental influences on behavioral outcomes associated with maternal anxiety and depression

Animal models of depression and anxiety: What do they tell us about human condition?

Interaction between maternal immune activation and postpartum immune stress in neuropsychiatric phenotypes

Maternal immune activation as an epidemiological risk factor for neurodevelopmental disorders: Considerations of timing, severity, individual differences, and sex in human and rodent studies

The recent progress in animal models of depression

Interaction of the pre- and postnatal environment in the maternal immune activation model

Epidemiology-driven neurodevelopmental animal models of schizophrenia

Mouse Models for Studying Depression-Like States and Antidepressant Drugs

Experimental animal models for the simulation of depression and anxiety

Animal inflammation-based models of depression and their application to drug discovery

Maternal Immune Activation and Endocannabinoid System: Focus on Two-Hit Models of Schizophrenia